{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:15:53Z","timestamp":1790673353064,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,23]],"date-time":"2022-01-23T00:00:00Z","timestamp":1642896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,23]],"date-time":"2022-01-23T00:00:00Z","timestamp":1642896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R50CA211241"],"award-info":[{"award-number":["R50CA211241"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA47904"],"award-info":[{"award-number":["P30CA47904"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA236367"],"award-info":[{"award-number":["R01CA236367"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["TL1TR001858"],"award-info":[{"award-number":["TL1TR001858"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"name":"COMMONWEALTH PA","award":["Tobacco Phase 18 Formula Funds 4100083102"],"award-info":[{"award-number":["Tobacco Phase 18 Formula Funds 4100083102"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s00280-021-04388-x","type":"journal-article","created":{"date-parts":[[2022,1,23]],"date-time":"2022-01-23T00:03:55Z","timestamp":1642896235000},"page":"231-242","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Dose-dependent bioavailability and tissue distribution of the ATR inhibitor AZD6738 (ceralasertib) in mice"],"prefix":"10.1007","volume":"89","author":[{"given":"Brian F.","family":"Kiesel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxia","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Parise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raman","family":"Venkataramanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Clump","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Bakkenist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8978-9401","authenticated-orcid":false,"given":"Jan H.","family":"Beumer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,23]]},"reference":[{"issue":"1","key":"4388_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13045-019-0733-6","volume":"12","author":"L Mei","year":"2019","unstructured":"Mei L, Zhang J, He K, Zhang J (2019) Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand. J Hematol Oncol 12(1):43. https:\/\/doi.org\/10.1186\/s13045-019-0733-6","journal-title":"J Hematol Oncol"},{"key":"4388_CR2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a012716","author":"A Marechal","year":"2013","unstructured":"Marechal A, Zou L (2013) DNA damage sensing by the ATM and ATR kinases. Cold Spring Harb Perspect Biol. https:\/\/doi.org\/10.1101\/cshperspect.a012716","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"4","key":"4388_CR3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s11538-021-00868-6","volume":"83","author":"EA Fedak","year":"2021","unstructured":"Fedak EA, Adler FR, Abegglen LM, Schiffman JD (2021) ATM and ATR activation through crosstalk between DNA damage response pathways. Bull Math Biol 83(4):38. https:\/\/doi.org\/10.1007\/s11538-021-00868-6","journal-title":"Bull Math Biol"},{"issue":"1","key":"4388_CR4","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1172\/JCI58928","volume":"122","author":"DW Schoppy","year":"2012","unstructured":"Schoppy DW, Ragland RL, Gilad O, Shastri N, Peters AA, Murga M, Fernandez-Capetillo O, Diehl JA, Brown EJ (2012) Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR. J Clin Invest 122(1):241\u2013252. https:\/\/doi.org\/10.1172\/JCI58928","journal-title":"J Clin Invest"},{"issue":"4","key":"4388_CR5","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1158\/1535-7163.MCT-16-0378","volume":"16","author":"A Min","year":"2017","unstructured":"Min A, Im SA, Jang H, Kim S, Lee M, Kim DK, Yang Y, Kim HJ, Lee KH, Kim JW, Kim TY, Oh DY, Brown J, Lau A, O\u2019Connor MJ, Bang YJ (2017) AZD6738, a novel oral inhibitor of ATR, induces synthetic lethality with ATM deficiency in gastric cancer cells. Mol Cancer Ther 16(4):566\u2013577. https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0378","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"4388_CR6","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41392-020-0150-x","volume":"5","author":"RX Huang","year":"2020","unstructured":"Huang RX, Zhou PK (2020) DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. Signal Transduct Target Ther 5(1):60. https:\/\/doi.org\/10.1038\/s41392-020-0150-x","journal-title":"Signal Transduct Target Ther"},{"key":"4388_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.crphar.2021.100017","volume":"2","author":"FM Barnieh","year":"2021","unstructured":"Barnieh FM, Loadman PM, Falconer RA (2021) Progress towards a clinically-successful ATR inhibitor for cancer therapy. Curr Res Pharmacol Drug Discov 2:100017. https:\/\/doi.org\/10.1016\/j.crphar.2021.100017","journal-title":"Curr Res Pharmacol Drug Discov"},{"issue":"3","key":"4388_CR8","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/s0167-8140(00)00236-x","volume":"56","author":"JW Hopewell","year":"2000","unstructured":"Hopewell JW, Trott KR (2000) Volume effects in radiobiology as applied to radiotherapy. Radiother Oncol 56(3):283\u2013288. https:\/\/doi.org\/10.1016\/s0167-8140(00)00236-x","journal-title":"Radiother Oncol"},{"key":"4388_CR9","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1159\/000106046","volume":"40","author":"R Timmerman","year":"2007","unstructured":"Timmerman R, Bastasch M, Saha D, Abdulrahman R, Hittson W, Story M (2007) Optimizing dose and fractionation for stereotactic body radiation therapy. Normal tissue and tumor control effects with large dose per fraction. Front Radiat Ther Oncol 40:352\u2013365. https:\/\/doi.org\/10.1159\/000106046","journal-title":"Front Radiat Ther Oncol"},{"issue":"1","key":"4388_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-019-0064-5","volume":"5","author":"D De Ruysscher","year":"2019","unstructured":"De Ruysscher D, Niedermann G, Burnet NG, Siva S, Lee AWM, Hegi-Johnson F (2019) Radiotherapy toxicity. Nat Rev Dis Primers 5(1):13. https:\/\/doi.org\/10.1038\/s41572-019-0064-5","journal-title":"Nat Rev Dis Primers"},{"issue":"26","key":"4388_CR11","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1200\/JCO.2014.55.1366","volume":"32","author":"ZS Morris","year":"2014","unstructured":"Morris ZS, Harari PM (2014) Interaction of radiation therapy with molecular targeted agents. J Clin Oncol 32(26):2886\u20132893. https:\/\/doi.org\/10.1200\/JCO.2014.55.1366","journal-title":"J Clin Oncol"},{"key":"4388_CR12","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1102\/1470-7330.2005.0012","volume":"5","author":"M Beasley","year":"2005","unstructured":"Beasley M, Driver D, Dobbs HJ (2005) Complications of radiotherapy: improving the therapeutic index. Cancer Imaging 5:78\u201384. https:\/\/doi.org\/10.1102\/1470-7330.2005.0012","journal-title":"Cancer Imaging"},{"issue":"6","key":"4388_CR13","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1097\/COC.0b013e3180ca7cb1","volume":"30","author":"BK Chang","year":"2007","unstructured":"Chang BK, Timmerman RD (2007) Stereotactic body radiation therapy: a comprehensive review. Am J Clin Oncol 30(6):637\u2013644. https:\/\/doi.org\/10.1097\/COC.0b013e3180ca7cb1","journal-title":"Am J Clin Oncol"},{"issue":"42","key":"4388_CR14","doi-asserted-by":"publisher","first-page":"44289","DOI":"10.18632\/oncotarget.6247","volume":"6","author":"FP Vendetti","year":"2015","unstructured":"Vendetti FP, Lau A, Schamus S, Conrads TP, O\u2019Connor MJ, Bakkenist CJ (2015) The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo. Oncotarget 6(42):44289\u201344305. https:\/\/doi.org\/10.18632\/oncotarget.6247","journal-title":"Oncotarget"},{"issue":"9","key":"4388_CR15","doi-asserted-by":"publisher","first-page":"3926","DOI":"10.1172\/JCI96519","volume":"128","author":"FP Vendetti","year":"2018","unstructured":"Vendetti FP, Karukonda P, Clump DA, Teo T, Lalonde R, Nugent K, Ballew M, Kiesel BF, Beumer JH, Sarkar SN, Conrads TP, O\u2019Connor MJ, Ferris RL, Tran PT, Delgoffe GM, Bakkenist CJ (2018) ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation. J Clin Invest 128(9):3926\u20133940. https:\/\/doi.org\/10.1172\/JCI96519","journal-title":"J Clin Invest"},{"issue":"11","key":"4388_CR16","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1158\/1078-0432.CCR-18-1821","volume":"25","author":"MT Dillon","year":"2019","unstructured":"Dillon MT, Bergerhoff KF, Pedersen M, Whittock H, Crespo-Rodriguez E, Patin EC, Pearson A, Smith HG, Paget JTE, Patel RR, Foo S, Bozhanova G, Ragulan C, Fontana E, Desai K, Wilkins AC, Sadanandam A, Melcher A, McLaughlin M, Harrington KJ (2019) ATR inhibition potentiates the radiation-induced inflammatory tumor microenvironment. Clin Cancer Res 25(11):3392\u20133403. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1821","journal-title":"Clin Cancer Res"},{"key":"4388_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000340","author":"H Sheng","year":"2020","unstructured":"Sheng H, Huang Y, Xiao Y, Zhu Z, Shen M, Zhou P, Guo Z, Wang J, Wang H, Dai W, Zhang W, Sun J, Cao C (2020) ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2019-000340","journal-title":"J Immunother Cancer"},{"issue":"5","key":"4388_CR18","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/path.5232","volume":"247","author":"AC Wilkins","year":"2019","unstructured":"Wilkins AC, Patin EC, Harrington KJ, Melcher AA (2019) The immunological consequences of radiation-induced DNA damage. J Pathol 247(5):606\u2013614. https:\/\/doi.org\/10.1002\/path.5232","journal-title":"J Pathol"},{"issue":"7","key":"4388_CR19","first-page":"1307","volume":"8","author":"LL Sun","year":"2018","unstructured":"Sun LL, Yang RY, Li CW, Chen MK, Shao B, Hsu JM, Chan LC, Yang Y, Hsu JL, Lai YJ, Hung MC (2018) Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing. Am J Cancer Res 8(7):1307\u20131316","journal-title":"Am J Cancer Res"},{"issue":"3","key":"4388_CR20","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/bjc.2017.376","volume":"118","author":"JS Brown","year":"2018","unstructured":"Brown JS, Sundar R, Lopez J (2018) Combining DNA damaging therapeutics with immunotherapy: more haste, less speed. Br J Cancer 118(3):312\u2013324. https:\/\/doi.org\/10.1038\/bjc.2017.376","journal-title":"Br J Cancer"},{"key":"4388_CR21","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jpba.2017.01.055","volume":"138","author":"BF Kiesel","year":"2017","unstructured":"Kiesel BF, Shogan JC, Rachid M, Parise RA, Vendetti FP, Bakkenist CJ, Beumer JH (2017) LC-MS\/MS assay for the simultaneous quantitation of the ATM inhibitor AZ31 and the ATR inhibitor AZD6738 in mouse plasma. J Pharm Biomed Anal 138:158\u2013165. https:\/\/doi.org\/10.1016\/j.jpba.2017.01.055","journal-title":"J Pharm Biomed Anal"},{"issue":"11","key":"4388_CR22","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1124\/dmd.117.077776","volume":"45","author":"BC Jones","year":"2017","unstructured":"Jones BC, Markandu R, Gu C, Scarfe G (2017) CYP-mediated sulfoximine deimination of AZD6738. Drug Metab Dispos 45(11):1133\u20131138. https:\/\/doi.org\/10.1124\/dmd.117.077776","journal-title":"Drug Metab Dispos"},{"key":"4388_CR23","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration (2018) Guidance for Industry-Bioanalytical Method Validation. U.S.Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research (CDER); Center for Veterinary Medicine (CVM),"},{"issue":"3","key":"4388_CR24","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/BF01062139","volume":"16","author":"AJ Bailer","year":"1988","unstructured":"Bailer AJ (1988) Testing for the equality of area under the curves when using destructive measurement techniques. J Pharmacokinet Biopharm 16(3):303\u2013309","journal-title":"J Pharmacokinet Biopharm"},{"issue":"6","key":"4388_CR25","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/j.1365-2125.1981.tb01304.x","volume":"12","author":"GT Tucker","year":"1981","unstructured":"Tucker GT (1981) Measurement of the renal clearance of drugs. Br J Clin Pharmacol 12(6):761\u2013770","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"4388_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003088-198409010-00001","volume":"9","author":"SM Pond","year":"1984","unstructured":"Pond SM, Tozer TN (1984) First-pass elimination. Basic concepts and clinical consequences. Clin Pharmacokinet 9(1):1\u201325. https:\/\/doi.org\/10.2165\/00003088-198409010-00001","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"4388_CR27","first-page":"1","volume":"39","author":"GR Wilkinson","year":"1987","unstructured":"Wilkinson GR (1987) Clearance approaches in pharmacology. Pharmacol Rev 39(1):1\u201347","journal-title":"Pharmacol Rev"},{"key":"4388_CR28","volume-title":"ADAPT 5 User\u2019s guide: pharmacokinetic\/pharmacodynamic systems analysis software","author":"DZS D'Argenio","year":"2009","unstructured":"D\u2019Argenio DZS, Wang X (2009) ADAPT 5 User\u2019s guide: pharmacokinetic\/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles"},{"issue":"5","key":"4388_CR29","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.steroids.2012.01.007","volume":"77","author":"JH Beumer","year":"2012","unstructured":"Beumer JH, Parise RA, Kanterewicz B, Petkovich M, D\u2019Argenio DZ, Hershberger PA (2012) A local effect of CYP24 inhibition on lung tumor xenograft exposure to 1,25-dihydroxyvitamin D(3) is revealed using a novel LC-MS\/MS assay. Steroids 77(5):477\u2013483. https:\/\/doi.org\/10.1016\/j.steroids.2012.01.007","journal-title":"Steroids"},{"issue":"8","key":"4388_CR30","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1002\/jps.2600830812","volume":"83","author":"K Watanabe","year":"1994","unstructured":"Watanabe K, Furuno K, Eto K, Oishi R, Gomita Y (1994) First-pass metabolism of omeprazole in rats. J Pharm Sci 83(8):1131\u20131134. https:\/\/doi.org\/10.1002\/jps.2600830812","journal-title":"J Pharm Sci"},{"issue":"15","key":"4388_CR31","doi-asserted-by":"publisher","first-page":"3510","DOI":"10.1158\/1078-0432.CCR-17-3102","volume":"24","author":"EP Hamilton","year":"2018","unstructured":"Hamilton EP, Patel MR, Armstrong AC, Baird RD, Jhaveri K, Hoch M, Klinowska T, Lindemann JPO, Morgan SR, Schiavon G, Weir HM, Im SA (2018) A first-in-human study of the new oral selective estrogen receptor degrader AZD9496 for ER(+)\/HER2(-) advanced breast cancer. Clin Cancer Res 24(15):3510\u20133518. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-3102","journal-title":"Clin Cancer Res"},{"issue":"5","key":"4388_CR32","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1211\/jpp\/61.05.0002","volume":"61","author":"K Thelen","year":"2009","unstructured":"Thelen K, Dressman JB (2009) Cytochrome P450-mediated metabolism in the human gut wall. J Pharm Pharmacol 61(5):541\u2013558. https:\/\/doi.org\/10.1211\/jpp\/61.05.0002","journal-title":"J Pharm Pharmacol"},{"issue":"6","key":"4388_CR33","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1517\/17425255.2.6.875","volume":"2","author":"M Martignoni","year":"2006","unstructured":"Martignoni M, Groothuis GM, de Kanter R (2006) Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2(6):875\u2013894. https:\/\/doi.org\/10.1517\/17425255.2.6.875","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"4388_CR34","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1124\/pr.115.011411","volume":"68","author":"JT Backman","year":"2016","unstructured":"Backman JT, Filppula AM, Niemi M, Neuvonen PJ (2016) Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev 68(1):168\u2013241. https:\/\/doi.org\/10.1124\/pr.115.011411","journal-title":"Pharmacol Rev"},{"issue":"9","key":"4388_CR35","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/00008571-200309000-00005","volume":"13","author":"F Lapple","year":"2003","unstructured":"Lapple F, von Richter O, Fromm MF, Richter T, Thon KP, Wisser H, Griese EU, Eichelbaum M, Kivisto KT (2003) Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics 13(9):565\u2013575. https:\/\/doi.org\/10.1097\/00008571-200309000-00005","journal-title":"Pharmacogenetics"},{"issue":"1","key":"4388_CR36","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1081\/dmr-100101915","volume":"31","author":"PE Scarborough","year":"1999","unstructured":"Scarborough PE, Ma J, Qu W, Zeldin DC (1999) P450 subfamily CYP2J and their role in the bioactivation of arachidonic acid in extrahepatic tissues. Drug Metab Rev 31(1):205\u2013234. https:\/\/doi.org\/10.1081\/dmr-100101915","journal-title":"Drug Metab Rev"},{"issue":"11","key":"4388_CR37","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1124\/dmd.30.11.1240","volume":"30","author":"S Matsumoto","year":"2002","unstructured":"Matsumoto S, Hirama T, Matsubara T, Nagata K, Yamazoe Y (2002) Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole. Drug Metab Dispos 30(11):1240\u20131245. https:\/\/doi.org\/10.1124\/dmd.30.11.1240","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"4388_CR38","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1172\/JCI34007","volume":"117","author":"KE Thummel","year":"2007","unstructured":"Thummel KE (2007) Gut instincts: CYP3A4 and intestinal drug metabolism. J Clin Invest 117(11):3173\u20133176. https:\/\/doi.org\/10.1172\/JCI34007","journal-title":"J Clin Invest"},{"issue":"2\u20133","key":"4388_CR39","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/s0169-409x(97)00043-4","volume":"27","author":"MF Hebert","year":"1997","unstructured":"Hebert MF (1997) Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev 27(2\u20133):201\u2013214. https:\/\/doi.org\/10.1016\/s0169-409x(97)00043-4","journal-title":"Adv Drug Deliv Rev"},{"issue":"6","key":"4388_CR40","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1021\/mp900253n","volume":"6","author":"LZ Benet","year":"2009","unstructured":"Benet LZ (2009) The drug transporter-metabolism alliance: uncovering and defining the interplay. Mol Pharm 6(6):1631\u20131643. https:\/\/doi.org\/10.1021\/mp900253n","journal-title":"Mol Pharm"},{"issue":"4","key":"4388_CR41","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1211\/jpp.62.04.0001","volume":"62","author":"J Vandenbossche","year":"2010","unstructured":"Vandenbossche J, Huisman M, Xu Y, Sanderson-Bongiovanni D, Soons P (2010) Loperamide and P-glycoprotein inhibition: assessment of the clinical relevance. J Pharm Pharmacol 62(4):401\u2013412. https:\/\/doi.org\/10.1211\/jpp.62.04.0001","journal-title":"J Pharm Pharmacol"},{"key":"4388_CR42","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.critrevonc.2016.01.010","volume":"100","author":"V De Sanctis","year":"2016","unstructured":"De Sanctis V, Bossi P, Sanguineti G, Trippa F, Ferrari D, Bacigalupo A, Ripamonti CI, Buglione M, Pergolizzi S, Langendjik JA, Murphy B, Raber-Durlacher J, Russi EG, Lalla RV (2016) Mucositis in head and neck cancer patients treated with radiotherapy and systemic therapies: literature review and consensus statements. Crit Rev Oncol Hematol 100:147\u2013166. https:\/\/doi.org\/10.1016\/j.critrevonc.2016.01.010","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"4388_CR43","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1177\/074823379701300401","volume":"13","author":"RP Brown","year":"1997","unstructured":"Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP (1997) Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13(4):407\u2013484. https:\/\/doi.org\/10.1177\/074823379701300401","journal-title":"Toxicol Ind Health"},{"issue":"1","key":"4388_CR44","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13014-018-1020-3","volume":"13","author":"G Frosina","year":"2018","unstructured":"Frosina G, Profumo A, Marubbi D, Marcello D, Ravetti JL, Daga A (2018) ATR kinase inhibitors NVP-BEZ235 and AZD6738 effectively penetrate the brain after systemic administration. Radiat Oncol 13(1):76. https:\/\/doi.org\/10.1186\/s13014-018-1020-3","journal-title":"Radiat Oncol"},{"issue":"4","key":"4388_CR45","first-page":"219","volume":"50","author":"EJ Freireich","year":"1966","unstructured":"Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE (1966) Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 50(4):219\u2013244","journal-title":"Cancer Chemother Rep"},{"issue":"13","key":"4388_CR46","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1158\/1538-7445.Am2017-ct084","volume":"77","author":"MT Dillon","year":"2017","unstructured":"Dillon MT, Espinasse A, Ellis S, Mohammed K, Grove LG, McLellan L, Smith SA, Ross G, Adeleke S, Woo K, Josephides E, Spicer JF, Forster MD, Harrington KJ (2017) Abstract CT084: A Phase I dose-escalation study of ATR inhibitor monotherapy with AZD6738 in advanced solid tumors (PATRIOT Part A). Cancer Res 77(13):84. https:\/\/doi.org\/10.1158\/1538-7445.Am2017-ct084","journal-title":"Cancer Res"},{"issue":"13","key":"4388_CR47","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/1538-7445.Am2018-ct026","volume":"78","author":"MG Krebs","year":"2018","unstructured":"Krebs MG, Lopez J, El-Khoueiry A, Bang Y-J, Postel-Vinay S, Abida W, Carter L, Xu W, Im S-A, Pierce A, Frewer P, Berges A, Cheung SYA, Stephens C, Felicetti B, Dean E, Hollingsworth SJ (2018) Abstract CT026: Phase I study of AZD6738, an inhibitor of ataxia telangiectasia Rad3-related (ATR), in combination with olaparib or durvalumab in patients (pts) with advanced solid cancers. Cancer Res 78(13):26. https:\/\/doi.org\/10.1158\/1538-7445.Am2018-ct026","journal-title":"Cancer Res"},{"issue":"15","key":"4388_CR48","doi-asserted-by":"publisher","first-page":"e14063","DOI":"10.1200\/JCO.2017.35.15_suppl.e14063","volume":"35","author":"A Pierce","year":"2017","unstructured":"Pierce A, Berges A, Cheung SYA, Standifer N, Ross G, Smith S, Hollingsworth SJ, Krebs M, Postel-Vinay S, Bang Y-J, El-Khoueiry AB, Abida W, Sundar R, Carter L, Castanon-Alvarez E, Im S-A, Lopez JS, Yap TA, Harrington K, Soria J-C (2017) Dose-exposure-response relationship between AZD6738 and peripheral monocytes. J Clin Oncol 35(15):e14063. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.e14063","journal-title":"J Clin Oncol"},{"issue":"13","key":"4388_CR49","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1158\/1538-7445.Am2018-ct118","volume":"78","author":"A Berges","year":"2018","unstructured":"Berges A, Cheung SYA, Pierce AJ, Dean E, Felicetti B, Standifer N, Smith S, Yates J, Lau A, Stephens C, Krebs M, Harrington K, Hollingsworth SJ (2018) Abstract CT118: PK-Biomarker-Safety modelling aids choice of recommended Phase II dose and schedule for AZD6738 (ATR inhibitor). Cancer Res 78(13):118. https:\/\/doi.org\/10.1158\/1538-7445.Am2018-ct118","journal-title":"Cancer Res"},{"issue":"7","key":"4388_CR50","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1023\/A:1018943613122","volume":"10","author":"B Davies","year":"1993","unstructured":"Davies B, Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10(7):1093\u20131095","journal-title":"Pharm Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04388-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-021-04388-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04388-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T17:40:02Z","timestamp":1643737202000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-021-04388-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,23]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["4388"],"URL":"https:\/\/doi.org\/10.1007\/s00280-021-04388-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,23]]},"assertion":[{"value":"18 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Bakkenist received sponsored research agreement funding from AstraZeneca in 2016-2018. The other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}